GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MicroPort CardioFlow Medtech Corp (HKSE:02160) » Definitions » Capex-to-Revenue

MicroPort CardioFlow Medtech (HKSE:02160) Capex-to-Revenue : 0.02 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MicroPort CardioFlow Medtech Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

MicroPort CardioFlow Medtech's Capital Expenditure for the six months ended in Jun. 2024 was HK$-5.84 Mil. Its Revenue for the six months ended in Jun. 2024 was HK$240.22 Mil.

Hence, MicroPort CardioFlow Medtech's Capex-to-Revenue for the six months ended in Jun. 2024 was 0.02.


MicroPort CardioFlow Medtech Capex-to-Revenue Historical Data

The historical data trend for MicroPort CardioFlow Medtech's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MicroPort CardioFlow Medtech Capex-to-Revenue Chart

MicroPort CardioFlow Medtech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial 2.27 0.56 0.54 0.20 0.09

MicroPort CardioFlow Medtech Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.26 0.14 0.12 0.06 0.02

Competitive Comparison of MicroPort CardioFlow Medtech's Capex-to-Revenue

For the Medical Devices subindustry, MicroPort CardioFlow Medtech's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MicroPort CardioFlow Medtech's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MicroPort CardioFlow Medtech's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where MicroPort CardioFlow Medtech's Capex-to-Revenue falls into.



MicroPort CardioFlow Medtech Capex-to-Revenue Calculation

MicroPort CardioFlow Medtech's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-33.377) / 367.745
=0.09

MicroPort CardioFlow Medtech's Capex-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-5.836) / 240.218
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MicroPort CardioFlow Medtech  (HKSE:02160) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


MicroPort CardioFlow Medtech Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of MicroPort CardioFlow Medtech's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


MicroPort CardioFlow Medtech Business Description

Traded in Other Exchanges
Address
No. 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, CHN, 201203
MicroPort CardioFlow Medtech Corp is a medical device company in China focusing on the research, development, and commercialization of transcatheter and surgical solutions for valvular heart diseases. The company's product portfolio consists of three products VitaFlow, VitaFlow Liberty, and Alwide Plus, and various TAVI products, TMV products, TTV products, surgical valve products, and procedural accessories. Geographically, it derives a majority of its revenue from China.
Executives
Microport Scientific Corporation 2201 Interest of corporation controlled by you
China Renaissance Holdings Limited 2201 Interest of corporation controlled by you
Hua Jie Tian Jin Yi Liao Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Shang Hai Hua Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Tian Jin Hua Jie Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Tian Jin Hua Qing Qi Ye Guan Li Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Shanghai Microport Limited 2101 Beneficial owner
China International Capital Corporation Limited 2201 Interest of corporation controlled by you
Cicc Capital Management Co., Ltd. 2201 Interest of corporation controlled by you
Cicc Kangrui I (ningbo) Equity Investment Limited Partners (limited Partnership) 2101 Beneficial owner
Cicc Kangzhi (ningbo) Equity Investment Management Co., Ltd. 2201 Interest of corporation controlled by you

MicroPort CardioFlow Medtech Headlines

No Headlines